Logo

Nanosphere, Lilly Ink PGx Test Alliance

Aug 11, 2009

NEW YORK (GenomeWeb News) – Nanosphere today said that has signed an agreement with Eli Lilly to develop pharmacogenetic assays that Lilly will use in its drug development efforts.

The Northbrook, Ill.-based molecular diagnostics developer said that it would develop the assays to run on its new Verigene SP system, which is a sample-to-result, bench-top, molecular diagnostics instrument. It is a random access system that does not require PCR amplification, said Nanosphere.

Terms of the alliance have not been disclosed.

Filed under

Diagnostics
pharmacogenomics
Luminex
Eli Lilly
Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.